JUPITER LIFE LINE HOSPITALS Q2 CONCALL : DOMBIVLI HOSPITAL NEARS EBITDA BREAKEVEN, EXPECTS HIGHER OCCUPANCY & ARPOB GROWTH; PUNE SOUTH EXPANSION ON TRACK

• MANAGEMENT EXPECTS DOMBIVLI HOSPITAL OCCUPANCY & ARPOB TO IMPROVE OVER THE NEXT 2–3 YEARS, SUPPORTED BY HIGHER PATIENT VOLUMES & SPECIALTY SERVICES • DOMBIVLI HOSPITAL APPROACHES EBITDA BREAKEVEN IN Q2 FY27, WITH LOSSES NARROWING SHARPLY FROM APPROXIMATELY ₹9.5 CR IN Q1 • MANAGEMENT MAINTAINS APPROXIMATELY TWO-YEAR EBITDA BREAKEVEN PLANNING ASSUMPTION FOR NEW HOSPITALS, DESPITE DOMBIVLI'S FASTER IMPROVEMENT • DOMBIVLI OCCUPANCY CURRENTLY AROUND 35%, PROVIDING SIGNIFICANT HEADROOM FOR FUTURE REVENUE GROWTH & OPERATING LEVERAGE • MANAGEMENT EXPECTS DOMBIVLI ARPOB TO GROW FASTER THAN INFLATION OVER THE NEXT 2–3 YEARS AS HIGHER-COMPLEXITY MEDICAL SERVICES EXPAND • RADIATION ONCOLOGY SERVICES AT DOMBIVLI EXPECTED TO COMMENCE IN Q3 FY27, WHILE TRANSPLANT SERVICES ARE TARGETED OVER THE NEXT COUPLE OF QUARTERS • DOMBIVLI DOCTOR RECRUITMENT EXPECTED TO CONTINUE FOR 12–18 MONTHS, SUPPORTING SPECIALTY EXPANSION & HIGHER PATIENT ADMISSIONS • INSURANCE EMPANELMENT PROCESS AT DOMBIVLI IS ONGOING, WITH MANAGEMENT INDICATING APPROXIMATELY ONE YEAR FOR COMPLETION • PUNE SOUTH HOSPITAL PROJECT REMAINS ON SCHEDULE, WITH ₹150 CR LAND ACQUISITION APPROVED & ₹100 CR ADDITIONAL CASH OUTFLOW EXPECTED • MIRA BANDRA HOSPITAL PROJECT EXPECTED TO PROGRESS TO ITS NEXT DEVELOPMENT PHASE BEFORE FY27-END, SUBJECT TO REGULATORY APPROVALS • BKC HOSPITAL PROJECT REMAINS IN PLANNING STAGE, WITH REGULATORY APPROVAL PROCESS EXPECTED TO COMMENCE • THANE HOSPITAL OCCUPANCY AT 75–80%, WITH LIMITED ADDITIONAL CAPACITY; FUTURE BED EXPANSION DEPENDS ON REGULATORY CLEARANCE • PUNE HOSPITAL OCCUPANCY AROUND 70%, WHILE INDORE OCCUPANCY REMAINS IN THE MID-TO-HIGH 50% RANGE; INDORE BED EXPANSION LIKELY AFTER OCCUPANCY REACHES MID-60% • MANAGEMENT EXPECTS OPERATING CASH CONVERSION TO REMAIN ABOVE 60% DESPITE HIGHER BORROWING COSTS, WHILE MAINTAINING A MAXIMUM DEBT LIMIT OF 3X EBITDA • Q2 REVENUE AT ₹456.5 CR, EBITDA AT ₹106.9 CR & EBITDA MARGIN AT 23.42%; DOMBIVLI SEASONALITY, INDORE MARGIN VOLATILITY, REGULATORY PRICING PRESSURE & EXPANSION-RELATED DEBT REMAIN KEY RISKS

JUPITER LIFE LINE HOSP L

← Back to feed